Inhaled drug developer Pulmatrix has announced the appointment of former Sunovion Respiratory and CNS Business Unit Head Ted Raad as Chief Business Officer. Raad was most recently Chief Commercial Officer at Option Care, the home infusion services subsidiary of Walgreens.
Pulmatrix CEO Robert Clarke said, “Ted is a proven leader in the commercial development of products with significant experience in respiratory indications and infectious diseases. His vision and skill set are perfectly suited to advance our pipeline products built around our proprietary iSPERSE inhaled dry powder technology. His later stage and commercial experience on asthma/COPD and anti-infective drugs is a perfect complement to the R&D and development expertise of the Pulmatrix team. We’re looking forward to Ted helping us build an integrated company that will bring needed therapies to patients and opportunities for investors.”
In 2016, Pulmatrix announced a collaboration with Capsugel to develop inhaled products based on the iSPERSE technology. Pulmatrix’s PUR1900 dry powder itraconazole has received both orphan drug and QIDP designations from the FDA.
Read the Pulmatrix press release.
